Castro, A, Diaz, P, Domingo, P, Garcia-Yubero, C, Losa-Garcia, JE, Castro, A, Vidal-Vilar, N, Aceituno, S. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain. Farmacia Hospitalaria. 2022; 46(6)DOI:10.7399/fh.13038. PMID:36520571. IF:(Q/D).

Domingo, P, Quesada-Lopez, T, Villarroya, J, Cairo, M, Gutierrez, MD, Mateo, MG, Mur, I, Corbacho, N, Domingo, JC, Villarroya, F, Giralt, M. Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. LIFE SCIENCES. 2022; 308DOI:10.1016/j.lfs.2022.120948. PMID:36096241. IF:6.100(Q1/2D).

Aparicio, J, Manrique, ACV, Capdevila, J, Boza, FM, Galvan, P, Richart, P, Oliveres, H, Paez, D, Hernando, J, Serrano, S, Vera, R, Hernandez-Yague, X, Gallego, RA, Riesco-Martinez, MC, de Albeniz, XG, Maurel, J. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). Clinical & Translational Oncology. 2022; 24(11)DOI:10.1007/s12094-022-02868-x. PMID:35761123. IF:3.400(Q3/6D).

Climent, MA, Font, A, Duran, I, Puente, J, Mendez-Vidal, MJ, Saez, MI, Lobera, CS, Arija, JAA, Gonzalez-Del-Alba, A, Sanchez-Hernandez, A, Fita, MJJ, Esteban, E, Alonso-Gordoa, T, Gonzalez, BM, Maroto, P, Lazaro-Quintela, M, Cassinello-Espinosa, J, Perez-Valderrama, B, Garcias, C, Castellano, D. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. EUROPEAN JOURNAL OF CANCER. 2022; 175DOI:10.1016/j.ejca.2022.08.002. PMID:36099670. IF:8.400(Q1/2D).